entertainment -WSS

entertainment

author：knowledge 2025-09-03 05:34:22 - browse：62

Adobe

WASHINGTON — The Biotechnology Innovation Organization, an industry trade group, is cutting ties with Chinese company WuXi in response to increasing U.S. government scrutiny of it and other Chinese companies, according to a BIO press release shared with STAT on Wednesday.

It’s an about-face for a lobbying organization that recently was willing to defend WuXi against attacks, and it’s a sign that the U.S. biotechnology industry will have to make do without a company that it has come to heavily rely on for developing and making drugs.

WuXi is the only BIO member among the four Chinese companies that would be blacklisted from doing business in the United States by the Biosecure Act, a bipartisan bill that has been introduced in both the House and Senate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Wikipedia

WSS

What is STAT's opinion section for?

NIH chief: government has fallen behind pharma on clinical trials

FDA does about

RSV vaccines may be linked to small increased risk of developing GBS

FDA reorg will put new emphasis on investigations, sources say

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

entertainment

entertainment

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

FDA does about

Alkermes shareholders re

House looks to weaken Medicare negotiation

Sports medicine is finally prioritizing gender equality

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Cancer drug shortages should be causing more outrage

FogPharma raises $145 million in rare Series E round

Supreme Court strikes down use of affirmative action

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

leisure time

NIH chief: government has fallen behind pharma on clinical trials

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Kenai launches with $82 million for Parkinson’s stem cell therapy

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Experimental asthma app from Apple and Anthem shows promise

UnitedHealth sued over use of algorithm in Medicare Advantage plans

knowledge

hotspot

explore

knowledge